Kimura Yuya, Suzukawa Maho, Jo Taisuke, Hashimoto Yohei, Kumazawa Ryosuke, Ishimaru Miho, Matsui Hiroki, Yokoyama Akira, Tanaka Goh, Yasunaga Hideo
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Clinical Research Center, National Hospital Organization Tokyo Hospital, Tokyo, Japan.
ERJ Open Res. 2024 Aug 12;10(4). doi: 10.1183/23120541.00122-2024. eCollection 2024 Jul.
The 2014 European Respiratory Society/American Thoracic Society guidelines defined severe asthma based on treatment intensity and estimated the proportion of severe asthma among all asthma cases to be 5-10%. However, data supporting the estimate and comprehensive and sequential data on asthma cases are scarce. We aimed to estimate the national prevalence and proportion of severe asthma during the last decade.
Using a Japanese national administrative database, which covers ≥99% of the population, we evaluated the prevalence and proportion of severe asthma in 2013, 2015, 2017 and 2019. Additionally, we elucidated the demographic characteristics, treatments and outcomes of patients with asthma.
The national prevalence of mild-moderate and severe asthma in 2019 was 800 and 36 per 100 000 persons, respectively. While the prevalence of mild-moderate asthma remained almost constant in the study years, the prevalence of severe asthma decreased, resulting in a reduction in the proportion of severe asthma from 5.6% to 4.3%. Although treatment modalities have evolved, such as the increased use of combination inhalers and asthma biologics, approximately 15% of mild-moderate and 45% of severe asthma cases were still considered "uncontrolled". The number of deaths from asthma decreased in patients with both mild-moderate and severe asthma.
This study revealed that the prevalence of severe asthma in Japan decreased during the study period and fell below 5% in the most recent data. Despite treatment evolution, a substantial proportion of patients with both mild-moderate and severe asthma still have poor asthma control.
2014年欧洲呼吸学会/美国胸科学会指南根据治疗强度定义了重度哮喘,并估计所有哮喘病例中重度哮喘的比例为5%-10%。然而,支持该估计的数据以及关于哮喘病例的全面且连续的数据较为匮乏。我们旨在估计过去十年间全国重度哮喘的患病率及所占比例。
利用覆盖≥99%人口的日本全国行政数据库,我们评估了2013年、2015年、2017年和2019年重度哮喘的患病率及所占比例。此外,我们还阐明了哮喘患者的人口统计学特征、治疗方法及治疗结果。
2019年轻度-中度哮喘和重度哮喘的全国患病率分别为每10万人800例和36例。在研究期间,轻度-中度哮喘的患病率几乎保持不变,而重度哮喘的患病率有所下降,导致重度哮喘所占比例从5.6%降至4.3%。尽管治疗方式有所发展,如联合吸入器和哮喘生物制剂的使用增加,但仍有大约15%的轻度-中度哮喘病例和45%的重度哮喘病例被认为“未得到控制”。轻度-中度哮喘患者和重度哮喘患者的哮喘死亡人数均有所下降。
本研究表明,在研究期间日本重度哮喘的患病率有所下降,最新数据显示该比例降至5%以下。尽管治疗有所进展,但仍有相当比例的轻度-中度哮喘患者和重度哮喘患者的哮喘控制不佳。